Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-07-28EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG
The EMA has withdrawn Inflectra (infliximab) from the market.
-
CLINICAL_TRIALS withdrawal · 2026-03-27Clinical Trial Update: Pregnancy and Medically Assisted Conception in Rare Diseases
Clinical trial NCT02450396 on pregnancy and medically assisted conception in rare autoimmune diseases has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
A clinical trial evaluating guselekumab for shared pathways in psoriasis, psoriatic arthritis, and nonalcoholic fatty liver disease has been…
-
EMA withdrawal · 2025-09-08EMA Withdrawn: Eksunbi (ustekinumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn Eksunbi (ustekinumab) from the European market as of 23 May 2025, affecting indications for Crohn's disease, ulcerativ…
-
CLINICAL_TRIALS withdrawal · 2025-02-13Clinical Trial Update: Enhanced Clinics for Patients Diagnosed With Ankylosing Spondylitis and Psoriatic Arthritis
The trial evaluating enhanced clinics for patients with ankylosing spondylitis and psoriatic arthritis has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-01-06EMA Application withdrawn: Apremilast Viatris (apremilast) — Viatris Limited
The European Medicines Agency has withdrawn Viatris Limited's application for apremilast (Viatris) for the EU market, terminating the market…
-
CLINICAL_TRIALS withdrawal · 2023-03-15Clinical Trial Update: Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis [Phase 4]
A Phase 4 trial evaluating bimekizumab in psoriasis vulgaris with active psoriatic arthritis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-07-23Clinical Trial Update: SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE [Phase 4]
A Phase 4 clinical trial exploring systemic inflammation and microvascular disease prevention in psoriasis and psoriatic arthritis has been …
-
CLINICAL_TRIALS withdrawal · 2021-05-13Clinical Trial Update: Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast [Phase 4]
Clinical trial update notes withdrawal of a Phase 4 study evaluating PsASon ultrasound scores in patients with Psoriatic Arthritis treated w…
-
EMA withdrawal · 2020-02-20EMA Lapsed: Lifmior (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency indicates Lifmior (etanercept) has lapsed; the product is no longer active in the market for its indicated con…
-
EMA withdrawal · 2019-03-06EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH
The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis su…
-
EMA withdrawal · 2019-03-05EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.
Solymbic (adalimumab) has been withdrawn from the market by Amgen Europe B.V.
-
CLINICAL_TRIALS withdrawal · 2017-07-17Clinical Trial Update: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study [Phase 2]
This clinical trial update reports that the Phase 2 study evaluating liraglutide for psoriatic arthritis (and related conditions) has been w…
-
CLINICAL_TRIALS withdrawal · 2017-04-07Clinical Trial Update: Psoriatic Arthritis Treat to Target vs. Usual Care [NA]
A clinical trial evaluating a treat-to-target approach versus usual care for psoriatic arthritis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-03-06Clinical Trial Update: Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα [Phase 3]
A Phase 3 trial evaluating antiviral prophylaxis for HBsAg-positive or HBcAb-positive/HBsAb-negative patients starting anti-TNF therapy has …
-
CLINICAL_TRIALS withdrawal · 2016-10-21Clinical Trial Update: Treatment With Apremilast in Patients With Psoriatic Arthritis [Phase 4]
A Phase 4 trial of Apremilast for psoriatic arthritis has been withdrawn.
-
EMA withdrawal · 2016-04-21EMA Withdrawn: Repso (leflunomide) — Teva B.V.
The EMA has withdrawn Repso (leflunomide) from the market, a disease-modifying antirheumatic drug previously used for rheumatoid arthritis a…
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
The study evaluating golimumab in Filipino patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis has been with…
-
CLINICAL_TRIALS withdrawal · 2012-08-10Clinical Trial Update: Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
The study evaluating Humira (adalimumab) for psoriatic arthritis, including safety, effectiveness, and effects on quality of life and work p…
-
EMA withdrawal · 2008-02-14EMA Withdrawn: Trudexa (adalimumab) — Abbott Laboratories Ltd.
EMA has withdrawn Trudexa (adalimumab) from the market.